Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)

Jeremy Shefner, Terry Heiman-Patterson, Erik P. Pioro, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang, Wendy Agnese, Stephen Apple*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Background: In a Phase 3 study, amyotrophic lateral sclerosis (ALS) patients experienced significantly less physical functional decline with 24-week edaravone vs placebo, followed by open-label treatment for an additional 24 weeks. Methods: Outcome (the change in ALS Functional Rating Scale–Revised, ALSFRS-R, from baseline) was projected for placebo patients through 48 weeks and compared with 48-week edaravone or 24-week edaravone after switching from placebo. Results: A total of 123 patients received open-label treatment (65 edaravone-edaravone; 58 placebo-edaravone). The projected ALSFRS-R decline for placebo from baseline through week 48 was greater than for 48-week edaravone (P <.0001). For patients switching from placebo to edaravone, ALSFRS-R slope approached that of continued edaravone for 48 weeks. ALSFRS-R decline did not differ between actual and projected edaravone through week 48. Conclusions: Compared with placebo, these analyses suggest that edaravone is beneficial in ALS patients even after 6 mo of receiving placebo, and efficacy is maintained for up to 1 year.

Original languageEnglish (US)
Pages (from-to)218-221
Number of pages4
JournalMuscle and Nerve
Volume61
Issue number2
DOIs
StatePublished - Feb 1 2020

Funding

p ‐value communications provided support for technical writing, editing, and publication assistance, and was funded by Mitsubishi Tanabe Pharma America, Inc. (MTPA). Study 19 was funded by Mitsubishi Tanabe Pharma Corporation (MTPC) and this post‐hoc analysis was funded by MTPA. MTPA and MTPC did not have any input in the manuscript beyond the input provided by the authors listed here.

Keywords

  • ALSFRS-R
  • chronic
  • disease progression
  • functional decline
  • linear regression
  • oxidative stress

ASJC Scopus subject areas

  • Clinical Neurology
  • Physiology (medical)
  • Cellular and Molecular Neuroscience
  • Physiology

Fingerprint

Dive into the research topics of 'Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)'. Together they form a unique fingerprint.

Cite this